Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects with Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) Allergy
This study is testing a new injection called PURETHAL Mites to see if it can help adults with hay fever-like symptoms or asthma caused by house dust mites. It compares the injection to a dummy treatment (placebo) to see if it reduces their allergy symptoms.
Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma Induced by House Dust Mite (HDM) AllergyLatvia - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
This study is looking into a new medicine, efgartigimod, for people with bullous pemphigoid (BP). It compares efgartigimod to a dummy drug (placebo) to see if it can help patients achieve clear skin without needing steroid tablets for a long time.
Bullous Pemphigoid (BP)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)
This study looks at the long-term safety and how well a medicine called soticlestat works for people with Dravet Syndrome or Lennox-Gastaut Syndrome. It's for those already in a previous study and focuses on side effects and overall health.
Dravet and Lennox-Gastaut SyndromesLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, double-dummy, multicenter, multinational study to assess the efficacy and safety of orally administered tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenously (IV) administered imipenem-cilastatin in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)
This study is looking at a new tablet treatment for serious urinary tract infections (UTIs) and kidney infections. It compares this new tablet with a standard IV (into the vein) treatment to see if it's safe and works well.
complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression FORTITUDE-101)
This study looks at a new drug, bemarituzumab, for advanced stomach or gullet cancer that hasn't been treated before. It aims to see if adding bemarituzumab to standard chemotherapy helps people live longer and improves their quality of life compared to chemotherapy alone.
Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpressionLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
This study is testing a new medicine, ZASOCITINIB (also called TAK-279), for people with moderate to severe plaque psoriasis. It compares the new medicine to existing treatments like Otezla and a dummy pill (placebo) to see how well it works and if it's safe.
Moderate to Severe Plaque PsoriasisLatvia - Ongoing, recruitingPhase II and Phase III (Integrated)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
This study is looking into a new treatment, AV-101, for Pulmonary Arterial Hypertension (PAH), a condition affecting the lungs and heart. It aims to see if the treatment is safe and effective by comparing it to a dummy medicine.
Pulmonary Arterial Hypertension (PAH)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
This study looks at the long-term safety of a new medicine, AV-101, for people with pulmonary arterial hypertension (PAH). It's for those who have already tried AV-101 in a previous study and aims to learn more about how well it's tolerated over time.
Pulmonary Arterial Hypertension (PAH)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
This study is looking into a new medication called Ozanimod for people with moderately to severely active Crohn's disease. Researchers want to see if it can help keep symptoms under control and reduce inflammation in the gut over time.
Moderately to Severely Active Crohn's DiseaseLatvia - AuthorisedTherapeutic use (Phase IV)
The role of meldonium and individualized physical activities in the treatment of patients with heart failure
This study is looking at how a medication called Meldonium, combined with personalised exercise, might help people in the UK who have a type of heart failure where their heart still pumps blood well but struggles to relax properly. It’s trying to see if this treatment can improve how much exercise they can do.
Chronic heart failure with preserved ejection fractionLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
This study is comparing a new version of a rheumatoid arthritis medicine, called DRL_AB, with an existing one, Orencia. It aims to see if the new medicine works as well, is safe, and causes a similar immune response in people with moderate to severe rheumatoid arthritis.
Rheumatoid ArthritisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This study is looking at a medicine called ozanimod for people with Crohn's disease that is moderate to severe. It wants to see how well the medicine helps reduce their symptoms and improve their gut health over a long period. Researchers will also check how it affects COVID-19 antibody levels.
Moderately to Severely Active Crohn's DiseaseLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy
This study is testing a medicine called NT 201 (also known as Xeomin) for children and teenagers with cerebral palsy who have stiff leg muscles. It aims to see if the medicine helps reduce the stiffness and improve movement, compared to a dummy treatment.
Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)Latvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
Relapsing Multiple SclerosisLatvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma
This study is testing a new treatment called STALORAL® Birch for children and teenagers aged 5 to 17 who suffer from hay fever (allergic rhinoconjunctivitis) caused by birch pollen. It looks at how safe and effective the treatment is, and if it could help with asthma too.
Birch Pollen-induced Allergic RhinoconjunctivitisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration
This study is testing a new version of an eye medicine, ranibizumab (like Lucentis), for wet age-related macular degeneration. Researchers want to see if the new version works as well and is as safe as the original to help people see better.
wet macula degenerationLatvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This study is looking at a new medicine called Danicopan for a type of age-related macular degeneration (AMD) called geographic atrophy (GA). Researchers want to see if the medicine can slow down vision loss and the growth of blind spots.
Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)Latvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
This study is testing a new medicine, REGN7508, to prevent blood clots after knee replacement surgery. It compares the new medicine with a standard blood clot prevention medicine, Inhixa/Clexane, to see how well it works and if it causes side effects.
Thromboembolic diseaseLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
Gastric and gastroesophageal junction (GEJ) adenocarcinomaLatvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Latvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
This study looks at a new medicine called Efavaleukin Alfa for people with moderate to severe ulcerative colitis. It's a long-term study to see how safe and effective the medicine is over a year or two, especially regarding side effects.
Ulcerative Colitis (UC)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency
This study is looking at a new way to give growth hormone treatment to children. Instead of daily injections, it's testing a weekly injection called Sogroya against the usual daily treatment, Norditropin. The main goal is to see if weekly Sogroya helps children grow as well as daily treatment.
Growth Hormone Deficiency in childrenLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin with or without metformin.
This study looks at a medicine called gliclazide MR to see if it helps people with type 2 diabetes whose blood sugar isn't well controlled, even when using other common diabetes medicines like dapagliflozin or metformin. It aims to see if it's safe and effective.
Type 2 Diabetes inadequately controlled with dapagliflozin with or without metforminLatvia - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Defining the Glucagon Unit: Investigating the Impact on Energy Expenditure and Glucose Level Deviation in healthy volunteers
This study for healthy men aged 18 and over investigates how different substances, including medicines for weight loss and hormones, affect the body's energy use and blood sugar levels. Researchers want to understand these effects to help treat conditions like obesity.
ObesityLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm)II and IIIA NSCLCLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
This study is testing a new medicine, Batoclimab, for people with an eye condition called Thyroid Eye Disease (TED). We want to see if this medicine can help reduce bulging eyes and improve other eye symptoms compared to a dummy medicine.
Thyroid Eye DiseaseLatvia - Ongoing, recruitingTherapeutic use (Phase IV)
Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia
This study is looking at a new way to lower 'bad' cholesterol (hypercholesterolemia). It compares a new medicine called Inclisiran with usual treatments, to see if it's safe and helps people feel better and reach their cholesterol goals.
HypercholesterolemiaLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod.
This study looks at how well a medicine called Kesimpta works for people with a type of multiple sclerosis called relapsing multiple sclerosis (RMS). It also checks for side effects and how people feel on the treatment, especially those switching from other MS medicines.
relapsing multiple sclerosis (RMS)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
This study looks at a new medicine called batoclimab for Thyroid Eye Disease (TED). It’s for people who have already taken part in similar batoclimab studies. We want to see how long their eyes stay improved after stopping the medicine and if it helps those who didn't respond before.
Thyroid Eye Disease (TED)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.
This study is looking at a new treatment called trimodulin for adults in hospital with pneumonia, including pneumonia caused by COVID-19. Researchers want to see if it makes people better and is safe to use compared to a dummy treatment.
Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)Latvia - Ongoing, recruitingPhase II and Phase III (Integrated)
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
This study looks at a new drug, abelacimab, compared to a standard drug, apixaban, for treating blood clots in veins (VTE) in people with cancer. The main goal is to see which drug is better at preventing new clots and causing less bleeding over six months.
venous thromboembolism (VTE)Latvia - Ongoing, recruitingPhase II and Phase III (Integrated)
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
This study looks at a new medicine called abelacimab for people with cancer-related blood clots. It compares abelacimab to a common blood thinner, dalteparin, to see which is better at preventing new clots and causing fewer bleeds.
venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancerLatvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesis
This study is testing a new medicine, Naronapride, for adults with stomach-emptying problems like gastroparesis. We want to see if it helps reduce symptoms like nausea and bloating, and if it's safe over 12 weeks.
Idiopathic or Diabetic GastroparesisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis
This study is comparing two medicines, AVT16 and Entyvio, for people aged 18-80 with moderate to severe ulcerative colitis. It will check how well they work, how safe they are, and how the body reacts to them over 52 weeks. The main goal is to see if symptoms improve after 6 weeks.
Moderate to Severe Active Ulcerative ColitisLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500μg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis
This study looks at new inhaled medications for people with a type of lung disease called COPD. It aims to see if these new medicines can help reduce flare-ups, improve breathing, and make everyday life better.
Chronic Obstructive Pulmonary Disease (COPD)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem Resistant Enterobacterales (OP0595-6)
This study looks at new medicines for serious bacterial infections like complicated urine infections, pneumonia, and tummy infections. Researchers want to see if these new treatments work better and are safer than current standard care, especially for infections resistant to common antibiotics.
Complicated urinary tract infection (cUTI)acute uncomplicated pyelonephritis (AP)hospital acquired bacterial pneumonia (HABP)ventilator-associated bacterial pneumonia (VABP)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.
This study compares a new medicine (BP11) with an approved one (Xolair) for chronic hives that haven't responded to usual treatments. Researchers want to see if BP11 is safe and effective in reducing itching and other symptoms.
Chronic UrticariaLatvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Neovascular Age-related Macular Degeneration (wet AMD)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults (OP0595-5)
This study is testing new medicines for serious urine infections. It compares them to a standard medicine to see if they are safe and work well for adults with complicated urine infections or kidney infections, checking if they clear the infection and make patients feel better.
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study looks at a new drug, OPT-302, combined with an existing treatment (Lucentis) for 'wet' age-related macular degeneration (AMD). It aims to see if the combination works better than Lucentis alone to improve or maintain vision over one year.
Neovascular age-related macular degeneration (wet AMD)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking at a new medicine called Vyvgart for people with Thyroid Eye Disease. It aims to see if the medicine can help reduce bulging eyes and improve eye health, compared to a dummy medicine, over 24 weeks.
Thyroid Eye Disease (TED)Latvia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)
This study is looking at the long-term safety of a medicine called Avacincaptad pegol for people with a serious eye condition called geographic atrophy. It's for those who have already been in a previous study using this medicine.
geographic atrophyLatvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
CDX0159-07: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Chronic Inducible Urticaria
This study is testing a new medicine called Barzolvolimab for people with chronic inducible urticaria (hives that can be triggered). It aims to see if the medicine can stop hives from appearing when triggered by cold or scratching, and if it's safe to use.
Chronic Inducible UrticariaLatvia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICENTER, OPEN-LABEL, EVALUATOR-BLINDED, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SINGLE-DOSE INTRAVENOUS ORITAVANCIN FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
This study is looking at how safe a new medicine called Oritavancin (also known as ORBACTIV or KIMYRSA) is for children with serious skin infections. Researchers want to see if it causes any problems when given as a single dose through a drip.
Acute Bacterial Skin and Skin Structure InfectionsLatvia - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisLatvia - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
This study is testing a new medicine, Verekitug, for people with moderate to severe COPD. It will check how well the medicine works and if it's safe. Participants will take Verekitug or a dummy pill alongside their usual COPD treatments.
Chronic Obstructive Pulmonary DiseaseLatvia - RecruitingPHASE3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.
Chronic Obstructive Pulmonary DiseaseLatvia - RecruitingPHASE3
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study is looking into a new medication called NBI-1065845 for people with depression who haven't fully responded to their current antidepressants. It will compare the new medication to a dummy pill (placebo) to see if it helps improve symptoms when added to existing treatment.
Major Depressive DisorderLatvia